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Abstract
Introduction Mammalian relative of DnaJ (MRJ [DNAJB6]), a
novel member of the human DnaJ family, has two isoforms. The
smaller isoform, MRJ(S), is studied mainly for its possible role in
Huntington's disease. There are no reports of any biologic
activity of the longer isoform, MRJ(L). We investigated whether
this molecule plays any role in breast cancer. Our studies were
prompted by interesting observations we made regarding the
expression of MRJ in breast cancer cell lines and breast cancer
tissue microarrays, as described below.
Methods Expression of MRJ(L) from several breast cancer cell
lines was evaluated using real-time PCR. Relative levels of the
small and large isoforms in breast cancer cell lines were studied
using Western blot analysis. A breast cancer progression tissue
microarray was probed using anti-MRJ antibody. MRJ(L) was
ectopically expressed in two breast cancer cell lines. These cell
lines were evaluated for their in vitro correlates of tumor
aggressiveness, such as invasion, migration, and anchorage
independence. The cell lines were also evaluated for in vivo
tumor growth and metastasis. The secreted proteome of the
MRJ(L) expressors was analyzed to elucidate the biochemical
changes brought about by re-expression of MRJ(L).
Results We found that MRJ(L) is expressed at a significantly
lower level in aggressive breast cancer cell lines compared with
normal breast. Furthermore, in clinical cases of breast cancer
expression of MRJ is lost as the grade of infiltrating ductal
carcinoma advances. Importantly, MRJ staining is lost in those
cases that also had lymph node metastasis. We report that
MRJ(L) is a protein with a functional nuclear localization
sequence. Expression of MRJ(L) via an exogenous promoter in
breast cancer cell line MDA-MB-231 and in MDA-MB-435 (a
cell line that metastasizes from the mammary fat pad) decreases
their migration and invasion, reduces their motility, and
significantly reduces orthotopic tumor growth in nude mice.
Moreover, the secreted proteome of the MRJ(L)-expressing cells
exhibited reduced levels of tumor progression and metastasis
promoting secreted proteins, such as SPP1 (osteopontin),
AZGP1 (zinc binding α2-glycoprotein 1), SPARC (osteonectin),
NPM1 (nucleophosmin) and VGF (VGF nerve growth factor
inducible). On the other hand, levels of the secreted metastasis-
suppressor KiSS1 (melanoma metastasis suppressor) were
increased in the secreted proteome of the MRJ(L)-expressing
cells. We confirmed by quantitative RT-PCR analysis that the
secreted profile reflected altered transcription of the respective
genes.
Conclusion Collectively, our data indicate an important role for
a totally uncharacterized isoform of DNAJB6 in breast cancer.
We show that MRJ(L) is a nuclear protein that is lost in breast
cancer, that regulates several key players in tumor formation and
metastasis, and that is functionally able to retard tumor growth.
AZGP1 = zinc binding α2-glycoprotein 1; DMEM = Dulbecco's modified Eagle's medium; EGF = epidermal growth factor; EGFP = enhanced green 
fluorescent protein; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; Hsp = heat shock protein; IDC = infiltrating ductal carcinoma; IRES = 
internal ribosome entry site; KiSS1 = melanoma metastasis suppressor; MRJ = mammalian relative of DnaJ; MRJ(L) = long isoform of MRJ; MRJ(S) 
= short isoform of MRJ; NFAT = nuclear factor of activated T cells; NLS = nuclear localization signal; NPM1 = nucleophosmin; PCR = polymerase 
chain reaction; RT = reverse transcription; SPARC = osteonectin; SPP1 = osteopontin; VGF = VGF nerve growth factor inducible.Breast Cancer Research    Vol 10 No 2    Mitra et al.
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Introduction
Mammalian relative of DnaJ (MRJ) is a class II DnaJ/heat shock
protein (Hsp)40 family protein [1,2]. The human MRJ gene has
been mapped to chromosome 7q36.3 and encodes two
spliced variants (reported in GenBank) [3]: isoform a (referred
to here as MRJ [L]) and isoform b (MRJ [S]). Murine MRJ has
been shown to be essential for murine placental development
[4]. MRJ(S) has also been implicated as an important chaper-
one in Huntington's disease [5,6]. Over-expressed MRJ(S)
effectively suppressed polyglutamine-dependent protein
aggregation, caspase activity, and cellular toxicity in neurons.
MRJ(S) specifically has also been shown to regulate keratin-8/
18 filament organization [7]. Interesting recent studies have
shown a role for MRJ(S) in blocking calcineurin-induced cardi-
omyocyte hypertrophy [8].
All studies of MRJ have focused on the shorter isoform (iso-
form b, 242 amino acids). Our study elucidates the role of the
longer isoform (isoform a, 326 amino acids) in breast cancer
cells. Here, we report for the first time that MRJ(L) levels are
almost undetectable in aggressive breast cancer cells and in
advanced grade infiltrating ductal carcinoma. MRJ(L) localizes
to the nucleus and suppresses tumorigenicity and metastasis
of breast cancer cells. Furthermore, cells expressing MRJ(L)
show an altered profile of the secreted proteome. Several
secreted proteins that are known to play important roles in pro-
moting cancer progression are downregulated. This is con-
comitant with upregulation of a breast and melanoma




MDA-MB-231 and MDA-MB-435 cells were maintained as
described before [9]. Transfected cells were grown in pres-
ence of 500 μg/ml G418 (Invitrogen, Carlsbad, CA, USA).
Cells of lines MCF10.DCIS.com, MCF10CAcl.a, and
MCF10CAcl.d were cultured in Dulbecco's modified Eagle's
medium (DMEM)/F12 with 5% horse serum, cholera toxin
(100 ng/ml), insulin (10 μg/ml), hydrocortisone (500 ng/ml)
and epidermal growth factor (EGF; 25 ng/ml). MCF7 was cul-
tured in DMEM/F12 containing 5% horse serum and insulin
(10 μg/ml). All cells were maintained at 37°C with 5% carbon
dioxide in a humidified atmosphere.
MCF10DCIS.com (locally aggressive) and metastatic variants
MCF10CAcl.a and MCF10CAcl.d are isogenic cell lines
derived from in vivo passages of MCF10AT (tumorigenic) in
nude mice [10,11]. These cell lines were obtained from the
Barbara Ann Karmanos Cancer Institute (Detroit, MI, USA).
MDA-MB-435 was reported to be derived from the pleural
metastases of a 46-year-old woman with breast carcinoma. It
forms progressively growing tumors that form metastases in
the lungs and regional lymph nodes after injection into the
mammary fat pads of 5-week-old athymic nude mice [12]. The
origin of MDA-MB-435 has been questioned because it
expresses melanoma-associated genes and is reported to
originate from the M14 melanoma line [13-15]. Its breast can-
cer origin was contested based on the fact that it expresses
milk proteins [16,17]. It is also pertinent to note that MDA-MB-
435 metastasizes from the mammary fat pad but rarely from
the subcutaneous site. In the present study this cell line was
used because it metastasizes from the mammary fat pad.
Plasmids and cell lines
MRJ(L) cDNA was subcloned into mammalian expression vec-
tor pIRES2-EGFP (Clontech, Mountain View, CA, USA) to
obtain pIRES2-EGFP-MRJ(L). MDA-MB-231 and MDA-MB-
435 cells were transfected with pIRES2-EGFP-MRJ(L). We
used the Lipofectamine 2000 reagent (Invitrogen). Briefly, 2 ×
106 cells were seeded in a 60 mm dish 1 day before transfec-
tion. Plasmid (8 to 10 μg) was mixed the Lipofectamine 2000
reagent, as recommended by the manufacturer. The DNA-
Lipofectamine 2000 complex (final volume 1 ml) was added to
the plate containing 4 ml serum-free DMEM/F12. Twelve
hours later the media were replaced with growth medium with-
out any selection. Transfection was monitored by examining
the tranfectants for the green fluorescence. Cells were
detached approximately 45 hours after transfection. Using
FACSVantage SE (Becton Dickinson), the top 20% fluores-
cent (enhanced green fluorescent protein [EGFP]) cells were
selected (correspondingly high MRJ [L] expressors because
of the internal ribosome entry site [IRES]). The expressor cells
were passaged in medium with G418. We used the
expressors as a pooled population to avoid any clonal varia-
tion. All cell lines were used within 10 to 12 passages to avoid
variations.
MRJ(L) with wild-type and mutant nuclear localization signal
(NLS) were cloned in frame with a carboxyl-terminal EGFP tag
in the vector pEGFP-N1. The wild-type NLS from amino acids
305 to 313 (KRKKQKQR) was mutated to (RPDRPETT) using
PCR. The corresponding plasmids are called as pEGFP-N1-
MRJ(L)WT and pEGFP-N1-MRJ(L)mut.
Collection of Serum free media and Western blot for 
secreted proteins
Cells (2 × 106) were plated in 10 cm plate containing appro-
priate growth medium overnight. The growth medium was
replaced with 3 ml serum-free phenol-free DMEM/F12. The
conditioned medium was harvested 18 hours later, spun at
1,300 rpm at 4°C for 10 minutes, and concentrated eightfold
using a Millipore Amicon Ultra 4 Centrifugal Filter Unit (Biller-
ica, MA, USA) with a 10 KDa cut-off. The concentrated condi-
tioned media samples were resolved on SDS-PAGE and
immunoblotted for proteins of interest.Available online http://breast-cancer-research.com/content/10/2/R22
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Immunoblotting
Plates (10 cm) at 90% confluence were washed twice with
calcium and magnesium-free phosphate buffered saline (PBS)
and lysed with cold lysis buffer (150 mmol/l NaCl, 50 mmol/l
Tris, 1% NP-40, and protease and phosphatase inhibitors).
The lysates were kept on ice for 1 hour and centrifuged at
10,000 rpm for 30 minutes at 4°C. Protein concentration was
measured using Bradford reagent (BioRad Laboratories, Her-
cules, CA, USA). Proteins (20 μg) were subjected to SDS-
PAGE and transferred to polyvinylidene fluoride membrane
(0.2 μm). The membranes were blocked with 5% skimmed
milk in Tris-buffered saline Tween-20 (1 mol/l Tris [pH 7.5],
9% NaCl and 0.05% Tween-20) and incubated with primary
antibodies overnight at 4°C. After washes in Tris-buffered
saline Tween-20 and incubation with the respective horserad-
ish peroxidase-tagged secondary antibody, the blots were
developed using SuperSignal™ (Pierce, Rockford, IL, USA).
For detection of MRJ, 5% milk in PBS containing 0.2% Tween-
20 was used, and for detection of osteopontin, 3% bovine
serum albumin in PBS containing 0.05% Tween was used as
blocking buffer.
We used the following antibodies (dilutions given in parenthe-
sis): anti-DNAJB6 antibody (1:5,000) from Abnova Corpora-
tion (Taipei City, Taiwan); anti-osteopontin (1:2,500) from
Sigma (St. Louis, MO, USA); anti-KiSS1 antibody (1:500)
from Abcam (Cambridge, MA, USA); anti-osteonectin
(1:1,000) from Haematologic Technologies Inc. (Essex Junc-
tion, VT, USA); anti-nucleophosmin (1:500) from Abcam; anti-
zinc α2-glycoprotein (1:500); anti-VGF nerve growth factor
(1:500) from Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA); and β-actin (1:30,000) from BioRad.
Wound healing assay
Cells were cultured to confluence on six-well plates, which
were previously externally marked with parallel lines to use as
guides for the subsequent photography. A central linear
wound (perpendicular to the guide lines) was made with a 200
μl sterile pipet tip. Media were changed gently to remove any
floating cells. Phase micrographs of the wound cultures were
taken at 0 and 16 hours (average doubling time is 18 to 20
hours). The photographs were analyzed by measuring the dis-
tance from the wound edge of the cell sheet to the original
wound site. Migration activity was calculated as the mean dis-
tance between edges in 12 fields per well. Each test group
was assayed in triplicate, and the results are expressed rela-
tive to vector control cell migration.
Migration and invasion assay
Migration and invasion assays were conducted using 8 μm
polyethylene terpthalate filters (BD Pharmingen, San Diego,
CA, USA), as described previously [18]. Cells migrated to the
lower sides of the trans-well were stained using Diff-Quik® rea-
gent (Diff Quik is from International Medical Equipment Inc.,
San Marcos, CA, USA) and the cell number was counted
under a microscope. Each test group was assayed in triplicate.
Four different fields of each insert were photographed at 10×
magnification using a Zeiss Axiocam 200 M microscope
(Zeiss Axiocam : Carl Zeiss Microimaging Inc. Thornwood, NY,
USA.). Each field was divided into quadrants, and cells in diag-
onally opposite quadrants were counted.
Soft agar colonization assay
Cells (2 × 103) suspended in 0.35% agar were plated onto a
layer of 0.75% bactoagar in DMEM/F12 (5% fetal bovine
serum) in six-well tissue culture dishes. Visible colonies (> 50
cells) were counted after 15 days with the aid of a dissecting
microscope [9].
Nuclear isolation
Nuclear protein extraction was performed as described previ-
ously [19]. Briefly, a confluent monolayer of cells was washed
twice in ice-cold PBS. Buffer A (10 mmol/l Hepes [pH 7.9], 10
mmol/l KCl, 0.1 mol/l EDTA, 200 μl of 10% IGEPAL, 1 mmol/
l DTT, and protease inhibitor cocktail) was added to the mon-
olayer and the plate was maintained at room temperature for
10 minutes. The lysate was spun at 15,000 g for 3 minutes at
4°C. The supernatant was saved as cytosolic fraction. The pel-
let was suspended in buffer B (20 mmol/l Hepes [pH 7.9], 0.4
mol/l NaCl, 1 mmol/l EDTA, 10% glycerol, 1 mmol/l DTT, and
protease inhibitor cocktail) and mixed vigorously for 2 hours at
4°C. The nuclear lysate was obtained by centrifuging at
15,000 g for 5 minutes at 4°C.
Confocal microscopy
COS7 or MDA-MB-231 cells were transfected with pEGFP-
N1-MRJ(L)WT  or pEGFP-N1-MRJ(L)mut  using Lipofectamine
2000 (Invitrogen), in accordance with the manufacturer's
instructions. Cells were visualized 32 hours after transfection
using Leica Microsystems TCS SP2 confocal microscope
with 63× water immersion objective (Leica Microsystems
Inc.Bannockburn, IL USA). Leica Confocal Software version
2.61 was used for data analysis and fluorescence/differential
interference contrast image overlays.
Tumor growth and metastasis assays
Cells (107 cells/ml) were re-suspended in ice-cold Hanks bal-
anced salt solution and 0.1 ml was injected into exposed axil-
lary mammary fat pads of anesthetized (ketamine 80 mg/kg,
xylazine 14 mg/kg), 6-week-old, female athymic mice (Harlan
Sprague-Dawley, Indianapolis, IN, USA). Tumor size was
measured weekly and mean tumor diameter was calculated as
previously reported [9]. The tumor growth was followed for a
period of 4 weeks.
The experimental metastasis assay was performed by injecting
2.5 × 105 MDA-MB-231 cells (in 0.2 ml Hanks balanced salt
solution) into the lateral tail vein of female athymic mice aged
3 to 4 weeks, as previously described [9]. After a period of 6
weeks, mice were killed; lungs were removed, rinsed withBreast Cancer Research    Vol 10 No 2    Mitra et al.
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PBS, and fixed in diluted Bouin's solution (20% Bouin's fixa-
tive in neutral buffered formalin) before quantification of sur-
face metastasis. For all of the experiments into tumor growth
and metastasis, eight mice were used per group and each
experiment was repeated once. Animals were maintained
under the guidelines of the National Institutes of Health and
Institutional Animal Care and Use Committee (IACUC) of the
University of South Alabama, Mobile. Food and water were
provided ad libitum.
Secreted proteome analysis
The analysis of secreted proteome was conducted as previ-
ously described [20]. Briefly, proteins from the conditioned
serum-free medium were concentrated using a tC2 reversed-
phase Sorbent column. The protein sample in 0.1% trifluoro-
acetic acid was loaded onto the cartridge and washed with
0.1% trifluoroacetic acid. Proteins were eluted with increasing
amounts of acetonitrile in 0.1% trifluoroacetic acid from 30%
to 70% at 0.1 ml/minute, concentrated to dryness, and
digested with trypsin. The resulting peptides were analyzed by
liquid chromatography-mass spectrometry. Electrospray tan-
dem mass spectrometry was performed with a Q-TOF Ultima
API-US mass spectrometer (Waters, Milford, MA, USA)
equipped with a nanoflow electrospray.
The resulting data files were searched using an in-house MAS-
COT search engine (version 2.1.03; Matrix Science Ltd, Lon-
don, UK) [21]. Ion scores higher than 35 (P < 0.05) were
considered significant. Only proteins matching at least two
peptides in MASCOT were accepted.
RNA isolation and cDNA synthesis and real-time 
quantitative RT-PCR
TRIzol reagent (Invitrogen) was used to isolate total RNA from
cultured cells. RNA was treated with DNase I (Promega, Mad-
ison, WI, USA). cDNA synthesis was carried out using a cDNA
synthesis kit (Applied Biosystems Inc., Foster City, CA, USA)
using 1 μg total RNA as the template and random primers.
Normal breast RNA was purchased from Clontech. Real-time
quantitative RT-PCR analysis was performed on the experi-
mental mRNAs. The PCR primers and probes for KiSS1,
nucleophosmin (NPM1), osteonectin (SPARC), osteopontin
(SPP1), zinc binding α2-glycoprotein 1 (AZGP1) and VGF
nerve growth factor inducible (VGF), and endorse control
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
were purchased from Applied Biosystems Inc. Quantative RT-
PCR was performed on an ABI 7500 HT instrument (Applied
Biosystems, Foster City, CA, USA). The gene expression Δ CT
values of mRNAs from each sample were calculated by nor-
malizing with internal control GAPDH and relative quantitation
values were plotted using SDS software v1.2 (Applied Biosys-
tems Inc.). Real-time quantitative RT-PCR analysis was per-
formed on the experimental mRNAs in triplicate, and the
experiment was repeated once from an independent passage
to confirm the findings.
Tissue array analysis
Breast carcinoma progression array (CC08-00-001) devel-
oped by Cybrdi Inc. (Frederick, MA, USA) was probed by
Cybrdi Inc. The arrays were stained by 1:100 dilution (10 μg/
ml) of DNAJB6 monoclonal antibody. Mouse IgG1 from Vector
PK-6102 (Vector Laboratories, Burlingame, CA, USA) was
used for the isotype background control. Photomicrographs
were taken in the area of most intense and diffuse staining for
MRJ. The intensity of staining of tumor cells was assessed as
0 (no staining) to 3 (strongest possible intensity of staining).
The immunoscore was derived as the product of the percent-
age of cells at each intensity and the corresponding intensity
[18]. The products were added to obtain an average immuno-
score for the group.
Statistical analysis
Statistical differences between groups were assessed using
the t-test or analysis of variance, using GraphPad Prism 4 sta-
tistical software (San Diego, CA, USA).
Ethics approval
The animal experiments were performed under protocol
#06042, approved by the IACUC committee of the University
of South Alabama, Mobile.
Results
MRJ(L) is expressed at a significantly lower level in 
breast cancer cell lines
We assessed the expression of MRJ(L) in breast cancer cell
lines using a real-time quatitative RT-PCR. As seen in Figure
1a, all breast cancer cell lines tested by us express very low
levels of MRJ(L) compared with the expression seen in normal
breast. However, among the cancer cell lines, MDA-MB-231
expressed MRJ(L) at a relatively high level.
We validated this observation at the protein level by an immu-
noblot for MRJ. As seen in Figure 1b, all cell lines exhibited a
clearly detectable level of MRJ(S) (28 kDa). Corresponding to
the quatitative RT-PCR data, the larger isoform MRJ(L) (38.6
kDa) was not detectable. Upon prolonged exposure, MDA-
MB-231 cells exhibited weakly detectable MRJ(L).
The expression of MRJ is lost in advanced breast cancer
We probed a breast carcinoma progression tissue microarray
using antibody specific to MRJ. The antibodies currently avail-
able are unable to distinguish between small and large iso-
forms. The results showed that 80% of the normal breast
cases (four out of five) were positive for MRJ staining. We also
found that among benign cases nearly half of the tissues
stained positive (48%), whereas in infiltrating ductal carci-
noma (IDC) cases (grades I and II) 50% cases stained positive
(six out of 12 cases). Importantly, only one out of 6 cases
(17%) of IDC grade III stained positive, whereas all six cases
of IDC with lymph node metastasis exhibited complete
absence of staining. Table 1 also outlines the averageAvailable online http://breast-cancer-research.com/content/10/2/R22
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immunoscores, which decrease with aggressiveness of the
tumor. Figure 1c shows intense nuclear and cytoplasmic stain-
ing in cystic hyperplasia (panel 1). In contrast, this staining is
absent in IDC grade III (panel 2).
There are two distinct isoforms of MRJ
The full length DNAJB6 isoform a (MRJ [L]) is comprised of
326 amino acids, whereas the shorter isoform b, (MRJ(S)), has
242 amino acids. MRJ(S) lacks the carboxyl-terminal 95 amino
acids of MRJ(L) but contains an additional 10 amino acids
(KEQLLRLDNK). Apart from the differences at the carboxyl-
terminus, both isoforms share identical structure, containing a
conserved J domain (70 amino acids) and a glycine/phenyla-
lanine domain (Figure 2a) [22].
MRJ(L) has a functional nuclear localization signal
PSORT II software (PSORT II is based on the collaboration of
Kenta Nakai, Ph.D.(Human Genome Center, Institute for Med-
ical Science, University ot Tokyo, Japan), with Paul Horton
(National Institute of Advanced Industrial Science and Tach-
nology, Tokyo, Japan.,) [23] predicted the presence of an NLS
in MRJ(L) from amino acids 305 to 320
(KRKKQKQREESKKKK). We constructed an in-frame fusion
of the NLS using requisite primers and PCR, and generated a
mutant NLS by inserting point mutations. The mutated NLS
sequence is RPDRPETTEESKKKK. Both the wild-type and
mutated NLSs were cloned into the pEGFP-N1 plasmid to
generate an in-frame EGFP fusion. Upon transfection of
COS7 cells with these constructs, we see that the wild-type
fusion protein MRJ(L)WT-EGFP is predominantly localized to
the nucleus, whereas the mutant NLS protein MRJ(L)mut-EGFP
exhibits a uniform distribution throughout the cell (Figure 2b).
Similar results were observed when the MRJ(L)WT-EGFP and
the MRJ(L)mut-EGFP fusion proteins were tested in breast can-
cer cell line MDA-MB-231. The analysis of nuclear and cyto-
plasmic protein fractions obtained from cells ectopically
expressing MRJ(L) (stable transfectants are described in the
following section) also reveals nuclear as well as cytoplasmic
localization of MRJ(L) in MDA-MB-231 and MDA-MB-435
cells. However, MRJ(S) was found to be almost exclusively
cytoplasmic (Figure 2c).
Cell lines ectopically expressing stable MRJ(L) were 
established
MDA-MB-435 and MDA-MB-231 cells were stably trans-
fected with MRJ(L)-pIRES2-EGFP as well as with the empty
vector. The transfectants were subjected to fluorescence-acti-
Figure 1
Expression of MRJ in breast cancer cell lines and tissues Expression of MRJ in breast cancer cell lines and tissues. (a) Expression of mammalian relative of DnaJ (MRJ) long isoform (MRJ [L]) is significantly 
lower in various breast cancer cell lines as compared with that observed in RNA from normal breast. Real-time quantitative RT-PCR was used to 
assess expression of MRJ(L) relative to endorse control gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The data are represented as 
fold change in the abundance of the MRJ(L) transcripts using commercially available normal breast RNA as a calibrator. Each reaction was carried 
out in triplicate, and the experiment was repeated once with RNA from the same cell lines at a different passage. The error bars represent the stand-
ard error. (b) Expression of MRJ isoforms in various breast cancer cell lines. An equal amount of protein lysate (20 μg) was resolved on SDS-PAGE 
and immunoblotted for levels of MRJ isoforms. Equal loading was confirmed by comparable β-actin signal. (c) Tissue microarray staining for MRJ. A 
breast carcinoma progression array (CC08-00-001; developed by Cybrdi Inc.) was stained by 1:100 dilution (10 μg/ml) of DNAJB6 monoclonal 
antibody. Mouse IgG1 was used for the isotype background control. Photomicrographs were taken in the area of most intense and diffuse staining 
for MRJ. The photomicrographs are representative images showing staining patterns of MRJ. Panel 1 corresponds to cystic hyperplasia, and panel 2 
corresponds to infiltrating ductal carcinoma grade III.Breast Cancer Research    Vol 10 No 2    Mitra et al.
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vated cell sorting to collect cells with greater fluorescence
intensity (top 20%). Because of the presence of an IRES, the
high fluorescence corresponds to high level of expression of
MRJ(L). This population shorted via fluorescence-activated
cell sorting was expanded by propagation using G418 resist-
ance and used for subsequent experiments. The expression of
MRJ(L) was confirmed by Western blot analysis (Figure 3a).
Analysis of in vitro attributes of tumor progression
The in vitro attributes of tumor progression were studied using
wound healing assay, invasion, migration and soft agar coloni-
zation. MRJ(L) expressors of MDA-MB-231 exhibited 50%
motility in a wound healing assay compared with the vector
control (Figure 3b). The trend was same for MRJ(L) expressors
of MDA-MB-435 MRJ(L), which exhibited 30% motility (Figure
3b). Expressors of MDA-MB-435 showed a highly reduced
(10% of vector control) capacity for anchorage-independent
growth when tested by colony formation ability in soft agar.
Moreover, the colonies that formed in MDA-MB-435-MRJ(L)
were small and grew much slower than did the vector control
(Figure 3c). The MDA-MB-231 cells did not exhibit a signifi-
cant change in the soft agar colonization, although the overall
trend appeared to be lower than vector control (data not
shown). Additionally MRJ(L) expressors of MDA-MB-231
exhibited reduced capacity to migrate (40% of the vector con-
trol) and invade (60% of the vector control) through Matrigel™
(BD biosciences San Jose, CA, USA) (Figure 3d, e). The
MRJ(L) expressors of MDA-MB-435 also exhibited reduced
migration (60% of the vector control) but showed a modest
decrease in invasion (85% of the vector control; Figure 3d, e).
MRJ(L) retards tumor growth and reduces lung 
colonization
The MRJ(L) expressing MDA-MB-231 and MDA-MB-435 and
the corresponding empty vector transfectants were independ-
ently assayed for orthotopic (mammary fat pad) tumor growth
in nude mice. The tumor growth of MRJ(L) expressors of both
the cell lines were found to be retarded when compared with
the empty vector control (Figure 4a, b).
The MRJ(L) expressing MDA-MB-231 cells exhibited a signifi-
cantly decreased (P  < 0.05) ability to establish pulmonary
metastases upon tail vein injection into athymic mice. The
MRJ(L) expressing cells showed 65% fewer lung metastases
compared with the vector control cells (Figure 4d).
The secreted proteome of the MRJ(L) expressors is 
altered
Conditioned cell-free and serum-free media from MRJ(L)
expressing MDA-MB-435 were compared with the corre-
sponding vector control. Our results (Table 2) show that
SPP1, SPARC, AZGP1, VGF, and NPM1 were notably down-
regulated in MRJ(L) expressors. Conversely, we also found
that the metastasis suppressor KiSS1 was upregulated in the
secreted proteome of MRJ(L)-expressing cells compared with
controls. Analysis of the serum-free medium by immunoblot
analysis confirmed that levels of SPP1, SPARC, VGF, NPM1,
and AZGP1 were below the limit of detection in MDA-MB-
435-MRJ(L) culture medium (Figure 5a). The increased
expression of KiSS1 in MRJ(L) expressors was confirmed by
analyzing the cell lysate (Figure 5a). We found that MDA-MB-
231 does not secrete SPP1 [24] and SPARC [25], which is
in agreement with previously reported findings. Also, it does
not secrete VGF and AZGP (data not shown). However,
Western blot analysis revealed increased level of KiSS1
expression and decreased level of NPM1 in MRJ(L) expressing
MDA-MB-231.
Determining changes in mRNA level of the key secreted 
proteins
We compared the expression levels of SPP1, AZGP1, VGF,
SPARC, NPM1, and KiSS1 using quantitative RT-PCR to
determine whether the change in the levels of secreted pro-
teome was due to change in transcription. Real-time PCR
comparison demonstrated reduced expression of SPP1 (17-
fold), AZGP (10-fold), VGF (9.4-fold), SPARC (7-fold) and
NPM1 (1.3-fold), and increased expression of KiSS1 (13-fold)
in MDA-MB-435-MRJ(L) cells compared with the vector con-
trol (Figure 5b).
Table 1
Immunostaining of MRJ is decreased in aggressive breast cancer specimen
Tissue type Total assessed Stained positive Percent positive IHC Scores
Normal 5 4 80 1.6
Benign 25 12 48 0.54
IDC stage I and II 12 6 50 0.45
IDC stage III 6 1 17 0.108
IDC with lymph node metastasis 6 0 0 0
A breast carcinoma progression array (CC08-00-001; developed by Cybrdi Inc.) was stained by 1:100 dilution (10 ug/ml) of DNAJB6 monoclonal 
antibody. Mouse IgG1 was used for the isotype background control. Photomicrographs were taken in the area of most intense and diffuse staining 
for mammalian relative of DnaJ (MRJ). The intensity of staining of tumor cells was assessed as 0 (no staining) to 3 (strongest possible intensity of 
staining). The immunoscore was derived as the product of the percentage of cells at each intensity and the corresponding intensity [18]. The 
products were added to obtain an average immunoscore for the group. IDC, infiltrating ductal carcinoma; IHC, immunohistochemistry.Available online http://breast-cancer-research.com/content/10/2/R22
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Discussion
Members of the DnaJ/Hsp40 proteins are highly conserved
and expressed in several tissues. They act as co-chaperones
regulating protein folding, transport, translational initiation, and
gene expression. The Hsp40 family of proteins is known to
have co-chaperonic activity. Involvement of the Hsp40 family
in tumorigenesis and malignant progression has yet to be com-
pletely elucidated. However, recent reports of the involvement
of some Hsp40 members of distinct classes such as hTid I
(class 3HDNAJA3) and HLJ1 (class DNAJB4) in modulation of
tumor growth are emerging [26-32].
DNAJB6 (MRJ) isoforms belong to the Hsp40 superfamily,
specifically class II. Our studies highlight the role of DNAJB6
isoform a, MRJ(L), as a negative regulator of tumor growth in
breast cancer. We found that MRJ(L) expression is low in
breast cancer cell lines. Constitutive expression of MRJ(L) in
highly aggressive breast cancer cell lines MDA-MB-231 and
MDA-MB-435 changes their in vitro and in vivo attributes of
malignancy. Our analysis of in vitro attributes of tumor pro-
gression and metastasis revealed reduced wound healing,
invasion, migration, and anchorage-independent growth. We
observed reduced tumor growth rate and decreased lung col-
onization upon injection of MRJ(L) expressing cells in nude
Figure 2
MRJ(L) localizes to nucleus MRJ(L) localizes to nucleus. (a) Comparison of the isoforms of DNAJB6 (mammalian relative of DnaJ [MRJ]). Various domains are indicated with dis-
tinct colors. Domains common to both DNAJB6 isoforms bear the same color code. Domains specific to each isoform bear unique color code. The 
nuclear localization signal (NLS) sequence is represented using single letter code for the amino acids. The amino acids underlined and in bold rep-
resent the strongest NLS. (b) COS7 cells were transfected with fusion protein pEGFP-N1-MRJ(L)WT or pEGFP-N1-MRJ(L)mut. Cells were visualized 
32 hours after transfection using a confocal microscope with 63× water immersion objective. MRJ(L)WT-EGFP was predominantly in the nucleus, 
whereas the mutant NLS protein, MRJ(L)mut-EGFP, exhibits a uniform distribution throughout the cell. (c) Equal protein from nuclear (N) and cyto-
plasmic (C) extracts (20 μg) from MRJ long isoform (MRJ [L]) expressors of MDA-MB-435 and MDA-MB-231 were analyzed for the presence of 
MRJ(L). Histone deacetylase 1 (HDAC1) was used as a marker to validate the purity of the nuclear fraction. β-Tubulin was used as cytoplasmic 
marker. MRJ(L) migrates at the apparent molecular weight of 38 kDa, MRJ short isoform (MRJ [S]) at 28 kDa, and HDAC1 at 55 kDa. EGFP, 
enhanced green fluorescent protein.Breast Cancer Research    Vol 10 No 2    Mitra et al.
Page 8 of 13
(page number not for citation purposes)
mice. These observations convincingly demonstrate a nega-
tive influence of MRJ(L) on tumor growth and metastasis.
The analysis of predicted domains of MRJ(L) revealed that
MRJ(L) has a nuclear localization signal. Confocal microscopy
studies using the EGFP fusion of MRJ(L) with wild-type or
mutated NLS showed that a significant amount of MRJ(L) is
localized to the nucleus, whereas the mutation in NLS ren-
dered it cytoplasmic. The continued presence of the MRJ(L)-
NLS-mut in the nucleus can be explained by the possibility that
there exists an additional cryptic NLS that the PSORT II soft-
ware may not have identified. Alternatively, MRJ(L) lacking the
NLS may still interact with another nuclear protein and could
be transported into the nucleus while attached to the other
protein, as indicated in the recent report by Cheng and cow-
orkers [22].
Secreted proteins play an important role in promoting tumor
growth and interaction with the local microenvironment and
facilitate its pathway to metastasis. MRJ(L) expressors of
MDA-MB-435 showed reduced secretion of SPP1, SPARC,
NPM1, VGF, and AZGP1, with concomitant increased expres-
Figure 3
Analysis of in vitro attributes of tumor progression Analysis of in vitro attributes of tumor progression. (a) Equal amounts (20 μg) of protein extracts from mammalian relative of DnaJ (MRJ) long isoform 
(MRJ [L]) expressors (M) of MDA-MB-231 and MDA-MB-435 were compared with the parent (P) and vector control (V) for the level of MRJ(L). 
MRJ(L) migrates at the apparent molecular weight of 38 kDa. Equal loading was confirmed by comparable β-actin signal. (b) MDA-MB-231-MRJ(L), 
referred to as 231-MRJ(L), and MDA-MB-435-MRJ(L), referred to as 435-MRJ(L), exhibited decreased migration compared with the corresponding 
vector controls (231-vec and 435-vec) in wound healing assay. Cells were cultured to confluence on premarked six-well plates. A central linear 
wound was made with a 200 μl sterile pipet tip. Phase micrographs of the wound cultures were taken at 0 and 16 hours. The photographs were ana-
lyzed by measuring the distance from the wound edge of the cell sheet to the original wound site. The dotted white lines in the photomicrographs 
indicate the original position of the wound. Migration activity was calculated as the mean of the distance between the edges in 12 independent fields 
per well. Each test group was assayed in triplicate, and the results are expressed relative to vector control cell migration. *P < 0.05. (c) MDA-MB-
435-MRJ(L) exhibited reduced anchorage-independent growth compared with vector control. Cells (2 × 103) suspended in 0.35% agar were plated 
onto a layer of 0.75% bactoagar in Dulbecco's modified Eagle's medium/F12 (5% fetal bovine serum) in six-well tissue culture dishes. Visible colo-
nies (> 50 cells) were counted after 15 days with the aid of a dissecting microscope. The results are expressed as mean number of colonies ± 
standard error of the mean. *P < 0.05. (d,e) MRJ(L) expressors of MDA-MB-231 and MDA-MB-435 exhibit significantly reduced ability to migrate 
through transwell (panel d) and are retarded in terms of their ability to invade through Matrigel™- coated filters (panel e). Migration and invasion 
assays were conducted using 8 μm polyethylene terphthalate filters, as previously described [18]. Cells migrated to the lower sides of the transwell 
were stained using Diff-Quik® reagent and the cells were counted under a microscope. Each test group was assayed in triplicate. Four different 
fields of each insert were photographed; each field was divided into quadrants and cells in diagonally opposite quadrants were counted.Available online http://breast-cancer-research.com/content/10/2/R22
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sion of KiSS1. We found that MDA-MB-231 does not secrete
VGF and AZGP1 or, as previously reported, SPP1 [24] and
SPARC [25]. However, MRJ(L) expression in MDA-MB-231
leads to increased KiSS1 and decreased NPM1.
SPP1 is an RGD-binding glycoprotein that plays a prominent
role in important steps in breast tumor growth and metastasis
[18,33,34]. SPARC has also been shown to regulate
adhesion and spreading of various types of tumor cells [35-
38]. Antisense oligonucleotides directed against SPP1 and
SPARC have been shown to inhibit proliferation and migration
of MDA-MB-231 cells [39]. Also, SPARC has been reported
to play a role in migration of breast cancer cells to bone [40].
However, there are conflicting reports about the precise role
of SPARC in breast cancer. A study conducted by Koblinski
and coworkers [25] indicated that SPARC expression inhibits
MDA-MB-231 metastasis. However, the primary tumor growth
rates (in vivo growth) of SPARC expressing MDA-MB-231
cells were not studied.
AZGP1 has been reported to be a potential quantitative
marker of differentiation grade of oral tumors [41]. It is
expressed by malignant prostatic epithelium and may serve as
a potential serum marker for prostate cancer [42]. The levels
of AZGP1 have been found to be higher in well differentiated
than in moderate or poorly differentiated breast tumors [43].
Relevance of VGF in breast cancer has not yet been explored.
However, peptide products of the neurotrophin-inducible
gene VGF are produced in human neuroendocrine cells from
early development and increase in hyperplasia and neoplasia
[44].
NPM1 is a 37 kDa phosphoprotein with nucleo-cytoplasmic
shuttling properties that is present at higher levels in prolifer-
ating cancer cells than in quiescent cells, and its increased
expression in hepatocellular carcinoma correlates with clinico-
pathologic parameters [45]. Interestingly, NPM1 is not
reported to be a secreted protein. Also, it lacks the traditional
signal sequence. However, it is predicted with high
confidence (by the Center for Biological Sequence Analysis
SecretomeP© 2.0 Server [46]) to undergo a nonclassical pro-
Figure 4
MRJ(L) retards tumor growth rate and metastasis MRJ(L) retards tumor growth rate and metastasis. (a,b) Mammalian relative of DnaJ (MRJ) long isoform (MRJ [L]) expressors and corresponding vec-
tor control cells (106/site) from MDA-MB-435 (panel a) and MDA-MB-231 (penal b) were injected into exposed axillary mammary fat pads of 6-week-
old, female athymic mice. Tumor size was measured weekly. Eight mice were used per group and the experiment was repeated once. The results are 
expressed as the mean tumor diameters ± standard error. (c) The experimental metastasis assay (lung colonization asay) was performed by injecting 
2.5 × 105 MDA-MB-231 cells (in 0.2 ml) into the lateral tail vein of 3- to 4-week-old, female athymic mice. After a period of 6 weeks lungs were 
removed and fixed with 20% Bouin's fixative in neutral buffered formalin before quantification of surface metastasis. Eight mice were used per group 
and the experiment was repeated once.Breast Cancer Research    Vol 10 No 2    Mitra et al.
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tein secretion. Nonclassically secreted proteins should obtain
an neural network output score (NN score) exceeding the nor-
mal threshold of 0.5; NPM1 has a score of 0.811.
The expression of KiSS1 (metastin) has been reported to
exhibit an inverse correlation with human tumor progression
and metastasis, and is either reduced or absent in various
types of cancers [47-49]. Over-expression of KiSS1 in meta-
static breast cancer cells or treatment of metastatic breast
cancer cells with synthetic KiSS1 has been shown to reduce
their metastatic potential [50,51]. Thus, the secreted pro-
teome analysis revealed important molecular players down-
stream of MRJ(L), and the changes in the secreted proteome
undoubtedly indicated a change from aggressive to nonag-
gressive phenotype. MRJ(L) expression upregulated KiSS1
and reduced the metastatic ability of the cells. It is important
to note that we have sequenced the KiSS1 mRNA from the
MRJ(L) expressors of MDA-MB-231 and MDA-MB-435 and
found no mutation in the resident KiSS1 sequence (data not
shown). Thus, the upregulated, resident KiSS1 protein is func-
tional as a metastasis suppressor. Also, it is tempting to spec-
ulate that MRJ(L) may play a similar role in regulating
melanoma metastasis by upregulation of KiSS1.
The changes in secreted protein levels could be due to several
factors such as altered secretion rate, altered stabilization of
proteins or altered transcription. The quantitative PCR analysis
shows that the influence of MRJ(L) on the secreted proteins is
at the transcriptional level, suggesting that MRJ(L) plays a role
in mediating regulation of transcription of these genes. In a
recent elegant study, Dai and colleagues [8] showed that the
MRJ(S) and nuclear factor of activated T cells (NFAT)c3 could
directly associate with one another in cardiomyocytes. Those
investigators also found that MRJ(S) served as a potent inhib-
Figure 5
Confirmation of changes in level of secreted proteins Confirmation of changes in level of secreted proteins. (a) The changes in the secreted proteome of mammalian relative of DnaJ (MRJ) long isoform 
(MRJ [L]) expressor observed by mass spectrometry were confirmed by Western blot analysis. Serum-free medium from equal number of MDA-MB-
435 parent (P), vector (V), MRJ(L) expressors (M) or MDA-MB-231 vector (V), and MRJ(L) expressors (M) was probed for presence of osteopontin 
(SPP1), osteonectin (SPARC), VGF nerve growth factor inducible (VGF), and zinc binding α2-glycoprotein 1 (AZGP1). Equal amount of total protein 
extract (20 μg) of the same cells was probed for the level of KiSS1 (melanoma metastasis suppressor); simultaneously, the expression of MRJ(L) 
was confirmed. β-Actin was used to verify equal loading of the lysate. Apparent molecular weights of the proteins detected are given in parenthesis: 
VGF (90 kDa), SPP1 (62 kDa), AZGP1 (47 kDa), SPARC (40 kDa), nucleophosmin (NPM1; 37 kDa), MRJ(L) (38 kDa), and KiSS1 (15 kDa). (b) 
Real-time quantitative RT-PCR analysis was performed using RNA from the MDA-MB-435-vector and MDA-MB-435-MRJ(L) expressor. The PCR 
primers and probes for KiSS1, NPM1, AZGP1, SPARC, SPP1, and VGF and endorse control gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) were used. The reaction was performed for up to 40 cycles in triplicate. The gene expression Δ CT values of mRNAs from each sample 
were calculated by normalizing with internal control GAPDH. The fold change is represented as 2-ΔΔCT. Real-time quantitative RT-PCR analysis was 
performed on the experimental mRNAs in triplicate and the experiment was repeated once from an independent passage.Available online http://breast-cancer-research.com/content/10/2/R22
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itor of NFAT transcriptional activity within the nucleus through
a mechanism involving histone deacetylase recruitment in con-
junction with heat shock. Heat shock is needed for the trans-
location of MRJ(S) from cytoplasm to the nucleus [8]. Thus, it
is tempting to speculate that MRJ(L) is capable of similar tran-
scription regulatory activities.
Tissue microarray analysis revealed that MRJ expression is lost
as IDC grades advance. Importantly, total absence of MRJ
staining in cases with lymph node metastasis was seen. The
MRJ antibody does not distinguish between isoforms, and so
we cannot comment on the presence or absence of each of
the isoforms. Because of small sample size, it is premature to
draw correlations between nuclear staining (which may corre-
spond exclusively to MRJ [L]) and disease stage. However, it
must be emphasized that none of the IDCs had positive
nuclear staining (n = 24), whereas there was a higher number
of positive nuclear staining in normal and benign (adenosis,
simple hyperplasia, atypical hyperplasia) lesions (eight out of
17 stained). In fact, one of the ways in which a tumor can gain
aggressive behavior is by spontaneous deletion or silencing of
the MRJ gene, which will lead to absence of both isoforms. It
is also likely that the expression of MRJ(S) is not ubiquitous in
tissues, in contrast to the expression observed in cell lines,
and this isoform may play similar or independent role(s) in reg-
ulating tumor growth.
Conclusion
In summary, we found that MRJ(L) plays an important role in
regulating breast cancer tumoriginicity and metastasis by
altering transcription of key players in cancer progression and
metastasis.
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